AU Patent

AU2023233122A1 — Osimertinib for use in the treatment of non-small cell lung cancer

Assigned to AstraZeneca AB · Expires 2023-10-05 · 3y expired

What this patent protects

The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKls) for use in the treatment of EGFR TKI-nave patients with locally-advanced or metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC), wherein the EGFR TKI is admin…

USPTO Abstract

The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKls) for use in the treatment of EGFR TKI-nave patients with locally-advanced or metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC), wherein the EGFR TKI is administered in combination with pemetrexed and platinum chemotherapy.

Drugs covered by this patent

Patent Metadata

Patent number
AU2023233122A1
Jurisdiction
AU
Classification
—
Expires
2023-10-05
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.